Source-grounded facts extracted from CHEMED CORP's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
CHEMED CORP shareholders rejected Executive Compensation at the 2026-05-18 meeting.
“Item 3. Executive Compensation. The proposal to approve, on a non-binding basis, the Company’s executive compensation program, was not approved with the following votes: Voted For 4,383,683 Against 6,926,656 Abstain 12,363 Broker non-votes 769,580”
CHEMED CORP shareholders approved Ratification of Independent Accountants at the 2026-05-18 meeting.
“Item 2. Ratification of Independent Accountants. The proposal to ratify the appointment of PricewaterhouseCoopers LLP by the Audit Committee of the Board of Directors as the company’s independent accountants for the year ending December 31, 2026, was approved with the following votes: Voted For 11,562,294 Against 523,129 Abstain 6,858 Broker non-votes -”
CHEMED CORP shareholders approved Election of Directors at the 2026-05-18 meeting.
“Stockholders voted on the matters set forth below: Item 1. Election of Directors. The following directors, who constitute the entire Board of Directors, were elected at the meeting by the votes indicated: Nominee For Against Abstentions Broker non-votes Kevin J. McNamara 11,111,578 204,388 6,735 769,580 Ron DeLyons 11,252,597 62,247 7,858 769,580 Patrick P. Grace 9,368,923 1,946,697 7,082 769,580 Christopher J. Heaney 10,891,279 424,319 7,104 769,580 Thomas C. Hutton 11,053,081 262,174 7,447 769,580 Andrea R. Lindell 10,642,996 672,859 6,847 769,580 Elaine McCarthy 11,173,021 141,697 7,984 769,580 John M. Mount Jr. 11,245,765 69,479 7,458 769,580 George J. Walsh III 10,007,160 1,308,559 6,983 769,580”
CHEMED CORP reported first quarter ended March 31, 2026 results: revenue $657.5 million, EPS GAAP Diluted Earnings-per-Share (EPS) of $4.84.
“quarter ended March 31, 2026, versus the comparable prior-year period. Results for Quarter Ended March 31, 2026 Consolidated operating results: · Revenue increased 1.6% to $657.5 million · GAAP Diluted Earnings-per-Share (EPS) of $4.84, a decrease of 0.4% · Adjusted Diluted EPS of $5.65, an increase of 0.4% VITAS segment operating results: · Net Patient Revenue”
CHEMED CORP incurred revolving credit of $450 million with JPMorgan Chase Bank, N.A. at secured overnight financing rate (“SOFR”) plus an additional tiered rate maturing five years.
“On April 10, 2026, Chemed Corporation (“Chemed” or "we") renewed our $450 million senior secured credit facilities (“Credit Facilities”).”
CHEMED CORP entered into Sixth Amended and Restated Credit Agreement with JPMorgan Chase Bank, N.A. valued at $450 million (effective 2026-04-10).
“On April 10, 2026, Chemed Corporation (“Chemed” or "we") renewed our $450 million senior secured credit facilities (“Credit Facilities”).”
CHEMED CORP reported first quarter ended March 31, 2024 results: revenue $589.2 million, EPS $4.24.
“· Revenue increased 5.2% to $589.2 million · GAAP Diluted Earnings-per-Share (EPS) of $4.24, an increase of 18.4% · Adjusted Diluted EPS of $5.20, an increase of 21.5%”
CHEMED CORP completed an acquisition involving Covenant Health and Community Services, Inc., d/b/a Covenant Care for $85 million (closed 2024-04-17).
“VITAS Healthcare Corporation (“VITAS”), a wholly-owned indirect subsidiary of Chemed, completed its acquisition of substantially all hospice operations and an assisted living facility from Covenant Health and Community Services, Inc., d/b/a Covenant Care, a Florida not for profit corporation (“Covenant”), for $85 million.”
CHEMED CORP reported the quarter ended December 31, 2023 results: revenue $585.9 million, EPS $5.90.
“Retention Program was $19.6 million and $14.6 million, respectively. Results for Quarter Ended December 31, 2023 Consolidated operating results: · Revenue increased 7.2% to $585.9 million · GAAP Diluted Earnings-per-Share (EPS) of $5.90, an increase of 42.9% · Adjusted Diluted EPS of $6.60, an increase of 35.0% VITAS segment operating results: · Net Patient”
David P. Williams changed role as Advisor to Chemed Corporation’s Chief Executive Officer at CHEMED CORP.
“To reflect his new role within the organization as an advisor to Chemed Corporation’s (the “Company’s”) Chief Executive Officer”
Michael Witzeman was appointed as Chief Financial Officer at CHEMED CORP.
“On December 18 th , the Company’s Board of Directors appointed Michael Witzeman as the Company’s Chief Financial Officer, effective as of January 1, 2024.”
David P. Williams departed as Executive Vice President and Chief Financial Officer at CHEMED CORP.
“On November 3, 2023, David P. Willaims advised Chemed Corporation (the “Company”) that he intends to retire effective December 31, 2023 as Executive Vice President and Chief Financial Officer of the Company.”
CHEMED CORP updated its quarter ended September 30, 2023 guidance (raised).
“On October 25, 2023, Chemed Corporation issued a press release announcing its financial results for the quarter ended September 30, 2023.”
CHEMED CORP reported third quarter ended September 30, 2023 results: revenue $565 million, EPS $4.93. Guidance raised.
“and after-tax expense for the Retention Program was $9.6 million and $7.1 million, respectively. Results for Quarter Ended September 30, 2023 · Revenue increased 7.2% to $565 million · GAAP Diluted Earnings-per-Share (EPS) of $4.93, an increase of 30.4% · Adjusted Diluted EPS of $5.32, an increase of 24.9% VITAS segment operating results: · Net Patient”
CHEMED CORP reported second quarter ended June 30, 2023 results: revenue $554 million, EPS $3.51. Guidance reaffirmed.
“Chemed Corporation (Chemed) (NYSE: CHE ), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its second quarter ended June 30, 2023, versus the comparable prior-year period, as follows: Consolidated operating results: · Revenue increased 4.2% to $554 million · GAAP Diluted Earnings-per-Share (EPS) of $3.51 · Adjusted Diluted EPS of $4.71, a decrease of 2.7%”
CHEMED CORP shareholders rejected Stockholder Proposal requesting stockholder ratification of termination pay at the 2023-05-15 meeting.
“Item 5. Stockholder Proposal. The proposal requesting stockholder ratification of termination pay, was not approved with the following votes: Voted For 6,498,338 Against 6,890,605 Abstain 26,772 Broker non-votes 743,025”
CHEMED CORP shareholders approved Frequency of advisory votes on executive compensation at the 2023-05-15 meeting.
“Item 4. Frequency of advisory votes on executive compensation. The proposal to hold an advisory vote on frequency of advisory votes on executive compensation, was approved with the following votes: Voted One year 13,012,902 Two years 118,686 Three years 258,661 Abstain 25,465 Broker non-votes 743,025”
CHEMED CORP shareholders approved Executive Compensation at the 2023-05-15 meeting.
“Item 3. Executive Compensation. The proposal to approve, on a non-binding basis, the Company’s executive compensation program, was approved with the following votes: Voted For 10,359,330 Against 3,020,668 Abstain 35,717 Broker non-votes 743,025”
CHEMED CORP shareholders approved Ratification of Independent Accountants at the 2023-05-15 meeting.
“Item 2. Ratification of Independent Accountants. The proposal to ratify the appointment of PricewaterhouseCoopers LLP by the Audit Committee of the Board of Directors as the company’s independent accountants for the year ending December 31, 2023, was approved with the following votes: Voted For 13,715,097 Against 436,826 Abstain 6,818 Broker non-votes -”
CHEMED CORP shareholders approved Election of Directors at the 2023-05-15 meeting.
“Item 1. Election of Directors. The following directors, who constitute the entire Board of Directors, were elected at the meeting by the votes indicated: Nominee For Against Abstentions Broker non-votes Kevin J. McNamara 13,177,032 221,781 16,901 743,025 Ron DeLyons 13,250,702 155,701 9,311 743,025 Patrick P. Grace 10,025,720 3,295,348 94,646 743,025 Christopher J. Heaney 13,026,990 379,514 9,210 743,025 Thomas C. Hutton 13,215,396 192,523 7,796 743,025 Andrea R. Lindell 12,704,541 623,870 87,304 743,025 Elaine McCarthy 13,392,362 15,603 7,749 743,025 John M. Mount Jr. 13,331,523 75,000 9,192 743,025 Thomas P. Rice 12,950,739 376,753 88,223 743,025 George J. Walsh III 11,270,147 2,137,074 8,493 743,025”
CHEMED CORP reported first quarter ended March 31, 2023 results: revenue $560 million, EPS $3.58.
“Chemed Corporation (Chemed) (NYSE: CHE ), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its first quarter ended March 31, 2023, versus the comparable prior-year period, as follows: Consolidated operating results: · Revenue increased 5.6% to $560 million · GAAP Diluted Earnings-per-Share (EPS) of $3.58 · Adjusted Diluted EPS of $4.82”
CHEMED CORP reported the fourth quarter ended December 31, 2022 results: revenue $547 million, EPS $4.13. Guidance initiated.
“Chemed Corporation (Chemed) (NYSE: CHE ), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its fourth quarter ended December 31, 2022, versus the comparable prior-year period, as follows: Consolidated operating results: · Revenue increased 1.0% to $547 million · GAAP Diluted Earnings-per-Share (EPS) of $4.13 · Adjusted Diluted EPS of $5.39”
CHEMED CORP: Adopted Amended and Restated By-Laws enhancing stockholder proposal and director nomination procedures, including universal proxy rules (effective 2022-12-09).
“On December 9, 2022, the Board of Directors (the “Board”) of Chemed Corporation (“Chemed”) adopted the Amended and Restated By-Laws of Chemed Corporation (the “By-Laws”), which became effective the same day.”
John M. Mount, Jr. was appointed as Director at CHEMED CORP.
“On August 5, 2022, the Board of Directors (the “Board”) of Chemed Corporation (the “Corporation”) appointed John M. Mount, Jr. as a member of the Board.”
CHEMED CORP reported third quarter ended September 30, 2022 results: revenue $526 million, EPS $3.78. Guidance raised.
“Consolidated operating results: · Revenue declined 2.3% to $526 million · GAAP Diluted Earnings-per-Share (EPS) of $3.78 · Adjusted Diluted EPS of $4.74, a decline of 6.3%”
John M. Mount, Jr. was appointed as Director at CHEMED CORP.
“On August 5 th , 2022, the Board of Directors of the Corporation appointed John M. Mount, Jr. to the Board, Mr. Mount is the North America Sports and Entertainment Marketing Team Lead at the Coca-Cola Company.”
Donald E. Saunders retired as Director at CHEMED CORP.
“Donald E. Saunders provided notice of his retirement from the Board of Directors of Chemed Corporation (the “Corporation”), effective as of 5:00 ET August 5, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.